Vestango has expert knowledge in building comprehensive and detailed business strategies for implementation in the pharmaceutical, medical, biotechnology market and broadly-defined areas of life sciences and healthcare in Poland.
Our experts’ knowledge and experience are supported by hundreds of successful and profitable business implementations in Poland.
Vestango has expert knowledge in building comprehensive and detailed business strategies for implementation in the pharmaceutical, medical, biotechnology market and broadly-defined areas of life sciences and healthcare in Poland. We work with products such as medicinal products, medical devices, dietary supplements, hygiene products, medical food, additives, products for animals and new technologies.
If you feel that your project requires a fresh perspective on your company processes, or that you need support in controlling your business in Poland – you can benefit from our support: we will analyse your product range, the formal and legal environment, the efficiency of your implementation processes, your sales strategy, as well as the areas of regulatory affairs and quality assurance.
If you feel that your business needs the support of professionals who will get involved in your project more than just executing an order, work on the cost and content side of things, define the strategy and bring capital to your company, looking at it as at their own business – you can invite us to your project and sell us shares.
Vestango can become your distributor or representative in Poland. We can set up a joint company or represent you before Polish authorities. We know the details and specifics of our local market. We will prepare a network of contacts. We can train your team in Poland. We can manage your company in Poland and represent your interests on the local market or help with your start-up.
Our experts are experienced in regulatory affairs and quality assurance. We can analyse the regulatory environment of the product you intend to launch in Poland for you – we will register it and check compliance of the composition and specifications with Polish regulations. We will analyse product descriptions and labelling. We will minimise legal risks associated with possible conflicts with the law on advertising of medicinal products or with attributing medicinal properties to products that do not meet the definition of a medicinal product in Poland.
We can assist with the preparation of medical, product and scientific arguments for the Polish market. We are experienced in the formulation of pharmaceutical products with a particular focus on the specificity of so-called borderline products, showing some characteristics of medicinal products and foodstuffs, including dietary supplements. We will carry out scientific and market research for you, and train your team if necessary.
January, 2024
1. Even 25% of Poles struggle with obesity. In Poland, awareness of the role of nutrition in maintaining proper health is growing, but sometimes there is confusion between the term’s treatment and nutrition. 2. In Poland, there is a noticeable problem with the availability of drugs containing semaglutide at certain times – these results from the increasing off-label use of medicinal products for weight loss purposes. In Poland, approximately 3 million people suffer from diabetes, with about 90% of this number dealing with type II diabetes. 3. Currently, there are as many as 224 medicinal products at risk of unavailability in Poland – this number is estimated by Polish competent authorities and may not encompass all actual needs identified by Polish doctors. 4. The share of the Polish pharmaceutical market on a global scale is less than 0.3%. Simultaneously, the potential of the workforce and the possibility of transferring solutions to other countries assume, in many areas, the level of a developed and investment-friendly state. Most Polish pharmaceutical and life sciences companies invest in innovation. 5. In Poland, there is a noticeable surge in the growth of sales in online pharmacies, showing a growth rate of 30% in recent years. 6. In Poland, there are fewer than 160,000 doctors, including approximately 130,000 doctors working with patients within the public system and private practices. 38 million Polish citizens rely on the support of medical professionals in their daily lives, including about 200,000 nurses – approximately 75% of all Polish nurses with the right to practice this profession. 7. Dentists (in most cases) and veterinarians in Poland work under exclusion from the public fund redistribution system. 35,000 dentists provide their services and help patients every day. 8. The number of Polish students exceeds 1.2 million – nearly 60% of them are women. It is worth noting that Polish students are an increasingly economically and technologically aware group of Polish citizens. 9. Polish women slightly more often reach for medicinal products (or food products suitable for health purposes) than men: 80% to 70%. In Poland, the market for “painkillers” is growing significantly, which are very often taken by Polish patients.
December, 2023
1. The average life expectancy in Poland is 81 years for women and 73 years for men. 2. Poles love pets – there are approximately 15 million dogs and cats in our country – meaning that roughly 1 dog or 1 cat is owned by every 3 residents of Poland, not to mention other species of companion animals found in Polish households. 3. In Poland, there are about 12 000 pharmacies, with the highest number registered in the Mazovian Voivodeship, where Warsaw, our capital, is located. 4. Polish taxpayers fund environmental protection costs at a level of around 0.5% of GDP. 5. Poland is an innovation hub – currently, there are over 3 000 startup companies operating in the country, representing more than 25% of all startups in our part of Europe – CEE. At the same time, half of them are directly or indirectly related to the life sciences industry. According to statistics, 1 in 10 of these startups has a chance to undergo positive market verification and become a serious business. 6. There are approximately 600 pharmaceutical raw materials/API registered in Poland. 7. Forest coverage in Poland is close to 30%. Polish forests are home to many species of protected animals, such as bison, wolves, and elk. 8. The total cost of establishing a company in Poland (including life sciences companies under the Limited Company structure) is less than USD 3,000. In Poland, there are also simpler forms of companies with a share capital of 25 cents – and the costs of establishing them can be compared to going to the cinema. 9. Until recently, up to 60% of investments in Polish life sciences projects focused on medical devices and therapeutic products – currently, with the same trends, there is a noticeable increase in medical innovations based on the current surge in artificial intelligence.
November, 2023
1. Currently, Poland boasts over 26,000 healthcare entities. 2. With more than 400 pharmaceutical wholesalers holding active licenses for the distribution of medicinal products. 3. Poland stands as one of the largest producers of generic medicines. 4. Over 20,000 dietary supplements for various needs are registered in Poland, and the market is continually growing. 5. Poland is an emerging market in the pharmaceutical industry, marked by a robust presence of local enterprises. Moreover, there are 22,000 registered medicinal products in Poland, with the potential for an increase in the number of registered products. 6. Serving as a hub for numerous life sciences initiatives within Europe. 7. Poland is home to some of the world’s finest incubators for AI-based medical devices and technological solutions, championed by med-tech innovators. 8. The Polish pharmaceutical market generates an impressive value exceeding $11.6 billion (USD). 9. The Polish consumer and patient are increasingly becoming examples of highly demanding consumers, creating further prospects for investments within our country.
1. Currently, in Poland, there are fewer than 38 million people, each of whom is a potential recipient of public or private healthcare – and each, in a direct or indirect way, benefits from products classified as medicinal, medical devices, or dietary supplements. 2. For every 100,000 people in Poland, the average incidence of malignant tumors is just below 0.5% – meaning statistically, 1 in 200 Poles develops malignant cancer. 3. Nearly half of malignant tumors in Poland affect the digestive or reproductive organs. 4. Currently, in Poland, there are even 900 hospitals in operation. 5. Out of the 38 million population in Poland, over 22 million reside in cities – the rural population in Poland is still high, but the eastern stereotype is fading, suggesting that less health-conscious patients live in Polish villages. 6. In Poland, the notification of a dietary supplement to the Polish Chief Sanitary Inspectorate takes 14 days – or rather, 14 days before the first introduction to the market, the product must be reported to the Polish Chief Sanitary Inspectorate, provided all quality requirements are met, and all ingredients are approved for use in food and dietary supplements. 7. In Poland, the registration of a simple Class I medical device takes 14 days – or rather, 14 days before the first introduction to the market, the product must be reported to the Polish registration office, provided the necessary documentation is available. 8. The average Polish mother becomes pregnant at just under 28 years of age. 9. In Poland, there are untapped opportunities for launching the production of many of the world’s most essential active substances – despite offering very favorable investment conditions and having qualified personnel, Poland currently relies mostly on substances imported from other countries, possessing the full potential to become a significant global producer of pharmaceutical products.
Our website uses cookies, which are saved on the disk of the user's end device in order to facilitate navigation and adapt the website to the user's preferences. Detailed information about cookies can be found in the Privacy Policy. Blocking the saving of cookies on the end device or deleting them is possible after properly configuring the settings of the web browser. You can find more about blocking and deleting cookies in the Privacy Policy. Blocking the possibility of saving cookies may cause difficulties or lack of operation of some website functions. Failure to change the web browser settings to settings blocking the saving of cookies is tantamount to consenting to their saving.
